Endocrine Abstracts

Introduction: Type 2 diabetes represents an important health problem and is designated by a progressive course. Since the vast majority of type 2 diabetic patients are overweight, there is a need not only to avoid weight gain but to lower body weight. Therefore, the usage of drugs that have the potential to lower body weight (GLP1 RA and SGLT2 -inhibitors) should with metformin be preferred initial therapy in the obese and overweight type 2 diabetic patients.

The aim of the study was to determine the efficacy of combination of dapagliflozin and lixisenatide in terms of glucose control and body weight change in type 2 diabetic patients.

Patients and Methods: 62 uncontrolled diabetic patients on metformin + DPP-IV inhibitor ± SU (32 male, 30 female, mean age 62.5±5.6 years, HbA1c 8.3±0.8%, BMI 38.7±3.2 kg/m² diabetes duration 7.2±3.2 years) were randomised to metformin+ lixisenatide (31 patients) or metformin + lixisenatide + dapagliflozin (31 patients) and followed for 6 months.

Results: A difference was observed in mean weight change −8.5±4.2 kg in the group treated with metformin + lixisenatide + dapagliflozin, and −5.1±4.7 kg in the metformin + lixisenatide group (P=0.09). No difference between the lixisenatide and lixisenatide + dapagliflozin group was observed concerning the percentage of subjects reaching HbA1c < 7% (47% vs 50%). No difference was found in reduction of HbA1c (1.27% vs 1.21%).

Conclusion: Combination of lixisenatide and dapagliflozin represents highly potent treatment option in obese and overweight patients.

Combination of lixisenatide and dapagliflozin resulted in significant reduction of weight in comparison to lixisenatide alone with metformin. Interestingly, no difference in HbA1c level between the two groups was found. These results suggest that effect on weight loss is additive, but without effect on glucose control.